Calcium Electroporation for the Treatment of Colorectal Cancer

Inclusion Criteria: * Histologically verified colorectal tumor * Conferred by multidisciplinary team (radiologists, surgeons and oncologists) discussing options possible for the patient, resulting in agreement that an endoscopic treatment with calcium electroporation should be offered to the patient. * Treatment free interval of minimum 2 weeks. * Thrombocytes ≥ 50 billions/l, INR \>1,2. Medical correction is allowed, e.g. correction of elevated INR by means of vitamin K. * Performance status ECOG/WHO ≤2 * Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.) * Trial subject ≥ 18 years. * Trial subject must be able to understand the participants' information. * Signed informed consent. The patients are considered participants in the study after signing of the informed consent. Exclusion criteria: * Coagulative disturbance that cannot be corrected * Pregnancy or lactation (Pregnancy is ruled out in fertile women by an HCG test in a blood sample) * Concurrent participation in other clinical trials that involve experimental drugs or participation in a clinical trial involving experimental drugs within 4 weeks prior to administration of the drug in this study. * Treatment with bevacizumab within the last 4 weeks. * Heavily inflamed colorectal mucus membrane with bleeding or ulcerations. * Implanted colon stent * Other clinical disease or previous treatments that make the investigator deem the patient unfit.